GMAB News and Press, Genmab A/S From 12/09/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 ...

Green Thumb Industries (OTC: GTBIF) , SunPower (NASDAQ: SPWR) and Genmab (NASDAQ: GMAB) are all up this month, and are trading for at least 35 times earnings. Instead of being overpriced, though, there are solid reasons investors see potential in these hot stocks. All th...

Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023 Epcoritamab could become the first subcutaneous bispecific antibody approved for the treatment of LBCL BLA submission supported by positive EPCORE™ NHL-1 trial results ...

The following slide deck was published by Genmab A/S in conjunction with their 2022 Q3 earnings call. For further details see: Genmab A/S 2022 Q3 - Results - Earnings Call Presentation

Deutsche Bank downgraded Genmab ( GMAB ) to hold from buy saying that it is does not expect upcoming data on candidates to be presented at two upcoming conferences to lead to upside. The firm has a price target of DKK 3100 (~3% upside based on Friday's close on the Copenhagen ...

Genmab A/S (GMAB) Q3 2022 Earnings Conference Call November 9, 2022 12:00 PM ET Company Participants Jan van de Winkel – Chief Executive Officer Anthony Pagano – Chief Financial Officer Tahi Ahmadi – Chief Medical Officer Conference Cal...

Genmab A/S press release ( GMAB ): Q3 GAAP EPS of DKK39.17. Revenue of DKK4.09B (+77.1% Y/Y). The company expects FY2022 net sales in the range of DKK13.5B to DKK14.5B from prior outlook of DKK12B to DKK13B. Operating profit to come in the range of DKK5.1B to DKK6.5B. ...

Genmab A/S ( GMAB ) is scheduled to announce Q3 earnings results on Wednesday, November 9th, before market open. The consensus EPS Estimate is $0.22 and the consensus Revenue Estimate is $486.47M (-78.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revi...

Summary As a company, Genmab has brought valuable medicines for patients. However, as a stock, it seems to be lagging, waiting for that blockbuster potential to be tapped. I will wait for a better price. I first covered Genmab A/S ( GMAB ) in December 2020, a...

Genmab ( GMAB ) on Thursday raised its 2022 revenue guidance on the back of a positive foreign exchange rate impact on its royalty revenue and strong net sales of cancer drug Darzalex. The Danish biotech now expects 2022 revenue to be in the range of DKK 13.5B to DKK ...